Harnessing deep learning
to prevent blindness

Learn how Eyenuk can help

Introducing EyeArt®

The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.

* EyeArt® has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.
** In the United States, EyeArt® is limited by federal law to investigational use only and is not available for sale.

EyeArt_Mac_Macbook_Mockups_img_withCEmark

How can EyeArt Help?

The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.

What does EyeArt Do?

The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.

How does EyeArt Work?

The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.

 

Why choose EyeArt?

The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.

* Claims on this page have not been evaluated by US FDA

Safe and effective in the real world

In a study with over 100,000 consecutive patient visits, EyeArt reports a 91.3% sensitivity and 91.1% specificity for referable DR and a 98.5% sensitivity for vision-threatening DR.

* These claims have not been evaluated by US FDA

Elevate Patient Care with the Confidence of AI Eye Screening

The high-performance EyeArt AI algorithm automatically detects diabetic retinopathy quickly, accurately, and consistently, with higher sensitivity than an eye care expert trained in image grading.

The EyeArt system is easy to use and with minimal training can be employed by nurses or technicians, enabling diabetic retinopathy screening at the point of care and eliminating an eye care specialist appointment just for screening.

Know More ▶

Elevate Patient v1

Undiagnosed Diabetic Retinopathy is a Thing of the Past

AI Eye Screening with EyeArt helps remove the biggest obstacle to annual DR screening and diagnosis: patient compliance.

The EyeArt system makes it possible for any physician to identify patients with vision-threatening retinopathy in-clinic, in real-time, so they can be immediately referred to an eyecare specialist for treatment to save their sight.

Know More ▶

Test and Give Results to Patients in the Same Appointment

Whether you work with diabetes patients as a general practitioner, endocrinologist, diabetologist, ophthalmologist, or an optometrist, EyeArt can enable fast, reliable, and accurate diabetic retinopathy screening for your patients.

Find out how easy it is to incorporate the EyeArt system into your practice.

Know More ▶

Want to try EyeArt?

EyeArt can be seamlessly integrated with your clinical workflow to enable automated DR screening.
Click to get started.

* EyeArt® has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.
** In the United States, EyeArt® is limited by federal law to investigational use only and is not available for sale.

Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a 3 part interview series.

Our Product Suite

Products under development. Click here to know more.

EyeMark

Accurately Track
Retinopathy Progression

EyeSee AMD

Fully-Automated
AMD screening

EyeSee Glaucoma

Fully-Automated Glaucoma screening

EyeApp

Mobile DR Screening
on your Phone

* EyeMark™, EyeApp™, EyeSeeAMD™, EyeSeeGlaucoma™ have not yet been cleared for sales in any region.

advisor-1

EyeArt could have a huge impact in improving the lives of individuals with diabetes who still face the risk of losing vision asymptomatically

Prof. Andrew Boulton, MD, DSc(Hon), FACP, FRCP

Renowned Diabetes Expert, Professor of Medicine, University of Manchester, UK
collaborators-2

I believe that an automated, reliable DR screening tool such as EyeArt would empower primary care providers to better manage their patients with diabetes.

Srinivas Sadda, MD

President and CSO, Doheny Eye Institute, Los Angeles, USA
collaborators-3

I believe that automation of common tasks like DR screening would have a tremendous impact on the quality and extent of vision care for the disparity populations. Therefore I am eager to work with EyeArt tool for DR screening.

Dr. Todd Margolis, MD, PhD

Distinguished Professor and Chairman, Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA (Former President of ARVO)
collaborators-1

...results of the large scale validation on over 100,000 patient encounters from the EyePACS database are highly encouraging and show that EyeArt can be a safe and effective alternative to manual screening.

Dr. Jorge Cuadros, OD, PhD

CEO of EyePACS, Assistant Clinical Professor, UC Berkeley School of Optometry, CA, USA
DrLaurenDaskivich

EyeArt’s automatic lesion detection and DR screening will allow us to better monitor our teleretinal patients at a lower cost in the under-resourced setting in which we care for Los Angeles’s most disadvantaged patients.

Dr. Lauren P. Daskivich, MD, MSHS

Director of Ophth. and Eye Health Programs, LA County Department of Health Services, Los Angeles, CA, USA

Eyenuk in the news

Select Collaborators, Customers, & Partners

The Doheny Eye Institute in Los Angeles, CA is recognized as a leading center for eye disease and vision research.

The Los Angeles County Department of Health Services safety net serves more than 800K patients annually and runs a teleretinal DR screening program.

Madras Diabetes Research Foundation (MDRF) in India was established in 1996. It's a premier research institute for diabetes and its complications.

Washington University School of Medicine, St. Louis, MO is one of the leading medical research, teaching and patient care institutions in the US.

The Armenian Eyecare Project (AECP) is a nonprofit organization dedicated to providing the Armenian people eye care to help eliminate preventable blindness.

Diabetes Clinic Bad Mergentheim (Germany) is a specialist hospital for inpatient diabetes treatment.

The National Health Service (NHS) is the public health service system of the United Kingdom. NHS runs the largest DR screening program in the world.

CAMO, the Ambrosian Ophthalmic Center, is an eye clinic of excellence, in Milan, for diagnostics, correction of visual defects and treatment of eye diseases.

Eye Picture Archive Communication System is a non-proprietary web-based application for exchanging eye-related clinical information.

Armenian EyeCare Project Surpasses Milestone of 10,000 Patients Screened Using Artificial Intelligence Eye Screening Technology

In cooperation with the World Diabetes Foundation and the Ministry of Health of Armenia, the Armenian EyeCare Project is implementing a nationwide screening program using state-of-the-art AI technology. 350 patients have already received sight-saving treatment...

Read More »

EyeArt study featured on AAO.org

Dr. Srinivas Sadda of Doheny Eye Institute presented new research at AAO 2019 that shows that EyeArt®, an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system...

Read More »

Using AI to Screen for Diabetic Eye Disease Feasible in the Real World

New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a...

Read More »

Eyenuk Receives NIH Grant To Expand AI Eye Screening Platform for Neurodegenerative Disease Detection

LOS ANGELES, Oct. 10, 2019 – Imagine if the very first signs of dementia, before any significant memory or other physiological changes are apparent, could be identified via a simple eye exam. That possibility may...

Read More »

Largest Peer-Reviewed Study on AI in Health Care Shows Real-World Significance of EyeArt AI Eye Screening System from Eyenuk

Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES, August 08, 2019 –  Eyenuk...

Read More »